Hims & Hers, a direct-to-consumer virtual care company, has added GLP-1 medications to their weight-loss program. Users will have access to generic and compounded injectable medications and oral medication kits starting at $199 a month. The company’s partnership with a U.S. manufacturer allows for more affordable and readily available medications compared to brand names like Ozempic and Wegovy. Studies continue to evaluate the safety of GLP-1 medications, with conflicting results on the risk of pancreatic carcinoma. Other companies, such as Lark Health and Noom, have also added GLP-1 offerings to their platforms for weight management.
Source link
Hims & Hers adds GLP-1 injections to weight loss program
